The effect of name-based reporting and partner notification on HIV testing in New York State.

Office of Program Evaluation and Research, AIDS Institute, New York State Department of Health, Riverview Center, 150 Broadway, Suite 516, Menands, NY 12204, USA.
American Journal of Public Health (Impact Factor: 4.23). 05/2008; 98(4):728-35. DOI: 10.2105/AJPH.2007.092742
Source: PubMed

ABSTRACT We examined the effect of New York's HIV Reporting and Partner Notification law on HIV testing levels and on the HIV testing decisions of high-risk individuals.
In-person interviews were administered to 761 high-risk individuals to assess their knowledge, attitudes, and behaviors regarding HIV testing and reporting. Trends in HIV testing were also assessed in publicly funded HIV counseling and testing programs, Medicaid, and New York's Maternal Pediatric Newborn Prevention and Care Program.
High-risk individuals had limited awareness of the reporting and notification law, and few cited concern about named reporting as a reason for avoiding or delaying HIV testing. HIV testing levels, posttest counseling rates, and anonymous-to-confidential conversion rates among those who tested HIV positive were not affected by the law. Medicaid-related HIV testing rates also remained stable. HIV testing during pregnancy continued to trend upward following implementation of the law. Findings held true within demographic and risk-related subgroups.
HIV reporting has permitted improved monitoring of New York's HIV/AIDS epidemic. This benefit has not been offset by decreases in HIV testing behavior, including willingness to test among those at high risk of acquiring HIV.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Public health officials and health providers need to be aware of the legislation documenting contact tracing in their jurisdiction to advise HIV positive clients of their rights, and to systematically perform their duties. The objective is to outline and compare the contact tracing laws in 13 jurisdictions in Canada, and to provide policy recommendations. A systematic review was performed to outline and compare the laws in Canadian jurisdictions regarding HIV contact tracing. Specific manual searches were done in websites of Canadian provincial and territorial departments of health. For thirteen provinces and territories within Canada eleven laws were found. No laws directly pertaining to partner notification or contact tracing were found in Newfoundland and Labrador or Quebec. Public health officials should ensure that contact tracing practices and policies accurately reflect the current regulations without compromising their patients' confidentiality. It is recommended that each province/territory would benefit from standardized contact tracing regulations which are imbedded in communicable disease legislation. Regulations with provisions for informed consent, confidentiality, multiple counselling sessions, clear procedures in duty to warn cases, and domestic violence screening would be considered best practice.
    Health Policy 08/2011; 103(2-3):111-23. DOI:10.1016/j.healthpol.2011.07.011 · 1.73 Impact Factor
  • Journal Européen des Urgences 05/2007; 20(1):18-18. DOI:10.1016/j.jeur.2007.03.113
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this study was to determine if anonymous and confidential testers differ in recency of human immunodeficiency virus (HIV) infection at time of testing and prevalence of antiretroviral drug (ARV) resistance. We examined data from the Centers for Disease Control and Prevention-sponsored Antiretroviral Drug Resistance Testing project, which performed genotypic testing on leftover HIV diagnostic serum specimens of confidentially and anonymously tested ARV-naïve persons newly diagnosed with HIV in Colorado (n = 365 at 11 sites) and King County, Washington (n = 492 at 44 sites). The serologic testing algorithm for recent HIV seroconversion was used to classify people as likely to have been recently infected or not. Type of testing, anonymous or confidential, was not significantly associated with either timing of HIV testing by serologic testing algorithm for recent HIV seroconversion or resistance rates. Mutations conferring any level of ARV resistance were present in 17% of testers, and high-level resistance mutations were present in 10%. Anonymous testers were significantly more likely to have CD4+ counts >500 cells per mm(3) (45% vs. 28%; p = 0.018), indicative of an early infection. This study indicates that anonymous testers have demographic differences relative to confidential HIV testers but were not more likely to exhibit drug resistance. Findings related to when in the course of disease anonymous testers are tested are inconsistent, but anonymous testers had higher CD4 counts, which indicates early testing and is consistent with other studies.
    Microbial drug resistance (Larchmont, N.Y.) 03/2011; 17(2):283-9. DOI:10.1089/mdr.2010.0066 · 2.52 Impact Factor

Full-text (2 Sources)

Available from
Sep 15, 2014